secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022133
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q3 revenue $7.0M, net loss $6.6M; closes Ameluz asset purchase
--------------------------------------------------------------------------

- Q3 2025 revenues $7.0M (down 22% YoY); 9-month revenues stable at $24.6M vs $24.8M.
- Net loss $6.6M vs $5.7M in Q3 2024; Adjusted EBITDA -$6.0M vs -$4.6M.
- Closed purchase of all U.S. assets for Ameluz and RhodoLED from Biofrontera AG; earnout reduced to 12-15% of net sales.
- Divested Xepi antibiotic cream to Pelthos Pharmaceuticals for $3M closing plus up to $6M milestones.
- Cash $3.4M at Sep 30; additional $2.5M received in Oct; runway extended by asset purchase and divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/0001493152-25-022133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer